Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice

British Journal of Pharmacology

Volumn 155, Issue 2, 2008, Pages 276-284

  Kreilgaard, M ^a   Smith, D G ^b   Brennum, L T ^a   Sanchez C ^b  

^a H LUNDBECK A S   (Denmark)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

5 HTP; Clinical predictions; MADAM; Mice; PK PD modelling; Serotonin reuptake inhibitors; SERT occupancy

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG POTENTIATION; DRUG RESPONSE; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; STEADY STATE;

ANIMALS; CITALOPRAM; MALE; MICE; MODELS, BIOLOGICAL; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 51349125593     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.243     Document Type: Article

References (32)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, American Psychiatric Press, Inc: Washington.
2. Asberg M, Eriksson B, Martensson B, Traskman-Bendz L, Wagner A (1986). Therapeutic effects of serotonin uptake inhibitors in depression. J Clin Psychiatry 47: 23-35.
3. Baumann P (1996). Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31: 444-469.
4. Bech P, Tanghoj P, Andersen HF, Overo K (2002). Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl) 163: 20-25.
5. Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG (2004). Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 7: 283-290.
6. Bundgaard C, Jorgensen M, Mork A (2007). An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents. J Pharmacol Toxicol Methods 55: 214-223.
7. Byerley WF, Risch SC (1985). Depression and serotonin metabolism: rationale for neurotransmitter precursor treatment. J Clin Psychopharmacol 5: 191-206.
8. Chen F, Larsen M, Sbnchez C, Wiborg O (2005). The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15: 193-198.
9. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V (2005). Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7: E544-E559.
10. Coppen A, Prange Jr AJ, Whybrow PC, Noguera R (1972). Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry 26: 474-478.
11. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544.
12. Gabrielsson J, Weiner D (2001). Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications, 3 edn, Swedish Pharmaceutical Press: Stockholm.
13. Harvey AT, Preskorn SH (1996). Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 16: 345-355.
14. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y et al. (2005). Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144: 695-702.
15. Hyttel J, Bogeso KP, Perregaard J, Sanchez C (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 88: 157-160.
16. Jesberger JA, Richardson JS (1985). Neurochemical aspects of depression: the past and the future? Int J Neurosci 27: 19-47.
17. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305: 625-631.
18. Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R et al. (2007). Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology 191: 333-339.
19. Korpi ER, Kleinman JE, Goodman SI, Phillips I, DeLisi LE, Linnoila M et al. (1986). Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims. Comparison in chronic schizophrenic patients with suicide as cause of death. Arch Gen Psychiatry 43: 594-600.
20. Larsen AK, Brennum LT, Egebjerg J, Sanchez C, Halldin C, Andersen PH (2004). Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol 141: 1015-1023.
21. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J (2000). Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 101: 354-359.
22. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K et al (2001). Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158: 1843-1849.
23. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ et al. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161: 826-835.
24. Murray CJ, Lopez AD (1996). Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274: 740-743.
25. O'Neil MF, Moore NA (2003). Animal models of depression: are there any? Hum Psychopharmacol 18: 239-254.
26. Olsen C, Brennum L, Kreilgaard M (2008). Using pharmacokinetic- pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol 584: 318-327.
27. Ortmann R, Bischoff S, Radeke E, Buech O, ini-Stula A (1982). Correlations between different measures of antiserotonin activity of drugs. Study with neuroleptics and serotonin receptor blockers. Naunyn Schmiedebergs Arch Pharmacol 321: 265-270.
28. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979). Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25: 358-371.
29. Sogaard B, Mengel H, Rao N, Larsen F (2005). The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 45: 1400-1406.
30. Wong DT, Bymaster FP, Engleman EA (1995). Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57: 411-441.
31. World Health Organization (1996). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected. Harvard School of Public Health: Cambridge.
32. Yassen A, Olofsen E, Dahan A, Danhof M (2005). Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 313: 1136-1149.